News

ORLANDO, FL / ACCESSWIRE / December 3, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its Chief Executive Officer Gareth Sheridan and President Serguei Melnik will be joined by members of the Company’s board of directors …

Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021 Read More »

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, has commenced the development of its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system. Following the Company’s recent successful uplisting to NASDAQ and financing, the company has started the commercial development …

Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl Read More »

ORLANDO, Fla., Nov 10, 2021 – Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal, topical and coated products, today announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report® on Bloomberg TV, November …

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report® Read More »

ORLANDO, FL / ACCESSWIRE / October 12, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products, today announced that it has signed an exclusive manufacturing agreement with San Diego-based Diomics for its Diocheck™ technology, a simple way for individuals …

Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch Read More »

ORLANDO, FL / ACCESSWIRE / October 4, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) …

Nutriband Inc.’s AVERSA(R) technology receives Notice of Allowance from United States Patent and Trademark Office (USPTO) Read More »

ORLANDO, Fla., Oct. 1, 2021 /PRNewswire/ — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, announced that its common stock and warrants began trading on the Nasdaq Capital Market effective October 1, 2021. Nutriband also announced the pricing …

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market Read More »

ORLANDO, Fla., Jan. 13, 2021 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, filed its form 8-K/A with the SEC for the audited financial reports of both Pocono Coated Products LLC and Active Intelligence and the combined pro forma financial statements with Nutriband Inc. About Nutriband Inc. The Company is primarily engaged in the development of …

Nutriband Inc. Files Pro Forma Financials Consolidating the Recent Acquisition of Pocono Coated Products Transdermal and Topical Business and Active Intelligence Read More »

ORLANDO, Fla., Dec. 15, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with RAMBAM Med Tech Ltd, a Division of the RAMBAM Hospital, the largest medical center in Northern Israel, for its Closed System Transfer Device designed to liquify drugs for patients who cannot swallow solids. The Closed System Transfer Device …

Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Hospital Group for its Closed System Transfer Device Read More »

ORLANDO, Fla., Dec. 16, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, is pleased to announce that it has reported record 2020 revenues for three and nine months ended October 31, 2020. In the third quarter of 2020, the Company recorded $391,797 in revenues as compared to $82,567 for the same period last year; for the nine months ended October 31, 2020 the Company recorded $595,611 in …

Nutriband Inc. Records Record 375% Year-Over-Year Increase in Third Quarter Revenues and Record 69% Increase for Its Nine Month Revenues Read More »

ORLANDO, Fla., Dec. 10, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the “Company”) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the ‘Abuse and Misuse Deterrent Transdermal Systems’ patent application filed by its clinical subsidiary 4P Therapeutics. The patent underpins 4p Therapeutics’ abuse deterrent fentanyl transdermal system, AVERSA, which uses Taste aversion …

Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its ‘Abuse and Misuse Deterrent Transdermal System’ Patent Read More »